Conservative Member of Parliament Corey Tochor introduced a private member’s bill on Tuesday aimed at legalizing the prescription of psilocybin, commonly known as magic mushrooms, to treat mental health disorders. Currently, psilocybin is a controlled substance in Canada, and possession or distribution remains illegal without federal authorization. Tochor’s proposed legislation seeks to remove current regulatory hurdles, allowing physicians to prescribe the substance directly to patients while directing Health Canada to grant it priority review status.
Did You Know? Since January 2022, Health Canada has issued only 354 authorizations for psilocybin usage, with data gathered by Conservative researchers indicating that approval rates for the drug have dropped to approximately 30 percent in recent months.
The Push for Legislative Change
Tochor, who represents the Saskatoon riding, stated that the bill is a response to a “mental health epidemic” and a desire to provide patients with greater freedom of choice. The MP was motivated by the case of his late constituent, Thomas Hartle, who struggled to obtain legal access to psilocybin for severe anxiety during his cancer treatments. Hartle passed away in 2024 at age 56, having traveled to the Caribbean multiple times to access the substance when domestic options were unavailable. Tochor argues that the current system is illogical, noting that while the government provides pathways for medical assistance in dying (MAID), it restricts access to a plant he describes as non-toxic and non-addictive.
Scientific and Clinical Perspectives
Research into the efficacy of psychedelics is gaining traction, though legal barriers remain a significant challenge. Danilo Bzdok, a professor at McGill University, recently co-authored a study published in Nature Medicine that used international imaging data to analyze how these drugs affect the brain. Bzdok found that psychedelics “reconfigure large-scale cortical organization,” suggesting they could serve as valuable clinical tools for mental health. He noted that while evidence of their effectiveness is accumulating, the current legal environment prevents broader study and application within the medical community.
Expert Insight: The proposal highlights a tension between emerging clinical research and established federal drug policy. While proponents emphasize “freedom of choice” and potential therapeutic benefits, the department of Health Canada maintains that psilocybin remains an experimental drug with unestablished safety and efficacy profiles. The legislative hurdle is significant, as private member’s bills rarely pass without government support, and this initiative faces the additional challenge of navigating a political climate where the current government has prioritized different approaches to the ongoing opioid crisis.
Potential Risks and Future Outlook
The use of psychedelics is not without risk, as experts and officials have identified several potential side effects. These include “bad trips” characterized by paranoia, hallucinations, extreme fear, or panic attacks, as well as possible cardiovascular and neurological complications. Tochor acknowledges these risks, arguing that the drug should be administered strictly within a clinical setting under a doctor’s care rather than through the existing “grey market” of illegal storefronts. If the bill fails to gain traction in Parliament, patients may continue to rely on the current, often cumbersome, Special Access Program or the illicit market, which has been subject to police raids and violence.
Frequently Asked Questions
[Why is psilocybin currently illegal in Canada?]
Under federal drug laws, it is a controlled substance, a classification established during the “war on drugs” when many Western nations restricted substances deemed dangerous or addictive.
[What is the Special Access Program?]
It is a Health Canada pathway that allows a limited number of patients to access psilocybin, though advocates describe the process as involving a “tangle of red tape” that can take over a year to navigate.
[What are the potential side effects of using psilocybin?]
Use can lead to “bad trips” involving hallucinations, confusion, or paranoia, and there are risks of neurological or cardiovascular conditions, as well as potential for psychosis or dangerous behavior.
Do you believe that clinical supervision is sufficient to mitigate the risks associated with the medical use of psychedelics?
